Targeted therapies from plant origin.

A non-hormonal, soybean-derived API targeting the estrogen receptors — without being recognized by the body as estrogen.

The Femarelle^® line provides a targeted solution to each stage of a woman's post-reproductive life:

• Femarelle^® Rejuvenate
  for the primary transition of estrogen decline — women 40+.
• Femarelle^® Recharge
  for the classical menopause transition — women 50+.
• Femarelle^® Unstoppable
  for the more mature woman — women 60+.

DT56a acts as a SERM — agonistic in tissues such as brain and bone, and blocking in reproductive tissues — declared 1st line treatment for menopause management at the European Society of Gynecology, 2017.

An overactive bladder leads to bothersome urinary symptoms — affecting more than half of men in their 50s and up to 90% of men in their 70s.

Brizo^® is intended for men suffering from irritable lower urinary tract issues associated with the aging of the prostate gland.

• Selective ERβ activation
  while restraining the stimulatory action of ERα.
• Androgen Receptor blocking
  preventing DHT from encouraging prostate proliferation.
• Relief within 1st month
  with lessened urinary urge during day and night.

A soybean-derived API selectively targeting the prostate gland — without unwanted effects.